Klaas Poelstra
Corporate Officer/Principal at University of Groningen
Klaas Poelstra active positions
| Companies | Position | Start | End |
|---|---|---|---|
| University of Groningen | Corporate Officer/Principal | 20/08/2009 | - |
Career history of Klaas Poelstra
Former positions of Klaas Poelstra
| Companies | Position | Start | End |
|---|---|---|---|
BiOrion Technologies BV
 BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Chief Tech/Sci/R&D Officer | 31/12/2002 | - |
| Founder | 20/08/2009 | - |
Statistics
International
| Netherlands | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Klaas Poelstra
- Experience
